US Pre-Market SEC Filings Roundup — August 19, 2026
This overnight filing cycle is dominated by a major M&A development in the protein sector, with JBS N.V. making a non-binding proposal to acquire the remaining ~18% of Pilgrim's Pride it does not own. The implied valuation offers no premium, creating a potential arbitrage opportunity but also signaling a lack of urgency from the buyer. Insider selling is the most prevalent theme, with notable disposals from executives at Roivant Sciences, Corpay, and Veradermics, suggesting management is taking profits at elevated levels. A significant governance battle is unfolding at Better Home & Finance, where the CEO's attempt to remove directors has led to a lawsuit, creating high uncertainty. On the positive side, a key regulatory condition (HSR waiting period) was cleared for argenx's acquisition of Forte Biosciences, moving that deal closer to completion. The filing set also includes a delisting notice for Skye Bioscience due to negative equity, and a large convertible note issuance by Datavault AI, indicating financial distress. Overall, the market is presented with a mix of high-stakes M&A, insider profit-taking, and corporate governance risks, with few clear bullish signals from operational results.